Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||JNJ-64264681 + JNJ-67856633|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|JNJ-64264681||JNJ 64264681|JNJ64264681||BTK inhibitor 33||JNJ-64264681 is a BTK inhibitor that blocks signaling through the BCR signaling pathway, potentially resulting in growth inhibition of tumor cells over expressing BTK (NCI Drug Dictionary).|
|JNJ-67856633||JNJ67856633|JNJ 67856633||JNJ-67856633 is an inhibitor that blocks the activity of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), resulting in decreased NF-kappaB and JAK/STAT signaling, potentially leading to increased apoptosis and decreased growth of MALT1-expressing tumor cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04657224||Phase I||JNJ-64264681 + JNJ-67856633||A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia||Active, not recruiting||USA | FRA | ESP | BEL||8|